The J.P Morgan Healthcare meeting wraps up Jan. 11 and as industry executives and investors depart San Francisco, the outlook for pharma appears bright in 2018, despite challenging fundamentals. The energy at the annual meeting, which drew more than 9,000 attendees, was more muted than prior years, perhaps highlighting the transition point pharma has reached.
Industry is trying to balance increasingly innovative science against long-standing drug development, regulatory, reimbursement and management models. Navigating those two...
